Remibrutinib improves sleep, daily activities in patients with CSU
28 Mar 2025
byElaine Soliven
Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, improved sleep and daily activities in patients with chronic spontaneous urticaria (CSU), according to two phase III REMIX-1 and -2 studies presented at AAD 2025.